SCHWIND appoints new head of global marketing solutions

News
Article

Lohith Shetty will lead marketing for the company, based in Kleinostheim, Germany

Lohith Shetty. Image courtesy of SCHWIND

Lohith Shetty. Image courtesy of SCHWIND

On Wednesday, SCHWIND eye-tech-solutions GmbH announced Lohith Shetty will join the ophthalmic technology company, based in Kleinostheim, Germany, as the new head of global marketing solutions. Shetty brings more than 13 years of experience in healthcare technology1 to the role; most recently, he served as a marketing manager for global strategic marketing and clinical content at ZEISS Medical Technology.

In a press release, SCHWIND described the role, putting an emphasis on Shetty’s client collaboration and opportunities for building relationships with SCHWIND technology’s end users. Additionally, in the global marketing role, Shetty will focus heavily on international distribution and making SCHWIND technologies more accessible worldwide. SCHWIND is a manufacturer of both diagnostic tools and treatment systems for ophthalmic conditions. The femtosecond laser SCHWIND ATOS and excimer laser SCHWIND AMARIS round out the refractive portfolio, while the SCHWIND MS-39, SIRIUS+ and PERAMIS provide imaging options for the anterior segment.

Domenic Von Planta, CEO of SCHWIND, said that Shetty’s appointment comes immediately following a major milestone for the company: production of its 100th SCHWIND ATOS femtosecond laser. “This is a testimony to the fact that we are well positioned for great growth in following years,” Von Planta said. He stated that the expansion to the leadership team comes at the perfect time to help meet SCHWIND’s production goals. “With onboarding of Lohith Shetty, we further reinforce our marketing efforts to achieve our ambitious vision,” Planta said.1

SCHWIND’s chief sales officer Lars Ederleh, who was appointed in summer 2023, also commented on Shetty’s expertise. “Lohith Shetty offers both specialist know-how and an understanding of the future requirements of our market,” Ederleh said. “His experience and expertise in the refractive segment are a major value add to our team. We look forward to working with him to further extend our global market position and increase demand for SCHWIND technologies in our target markets.”

Reference
  1. SCHWIND. New Head of Marketing at SCHWIND eye-tech-solutions. Published 17 April 2024. Accessed 17 April 2024.
Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.